Anti-cancer compounds

Patent metadata

Field	Value
Publication number	US-10745355-B2
Application number	US-201615547227-A
Country	US
Kind code	B2
Filing date	Jan 29, 2016
Priority date	Jan 30, 2015
Publication date	Aug 18, 2020
Grant date	Aug 18, 2020

Abstract

The present invention relates to new pharmaceutical agents, and to their use in the treatment of proliferative diseases, such as cancer (in particular, brain cancer).

First claim

The invention claimed is:

1. A compound selected from the group consisting of

2. A pharmaceutical composition comprising the compound according to claim 1 , together with a pharmaceutically acceptable carrier, diluent or excipient.

3. A method of treating a solid tumor in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to claim 1 .

4. A method of treating a solid tumor in a subject in need thereof comprising administering to the subject a pharmaceutical composition according to claim 2 .

5. The method according to claim 3 , wherein the solid tumor is a brain cancer.

6. The method according to claim 4 , wherein the solid tumor is a brain cancer.

7. The method according to claim 5 , wherein the brain cancer is selected from anaplastic astrocytoma, astrocytoma, central neurocytoma, choroid plexus carcinoma, choroid plexus papilloma, choroid plexus tumour, diffuse intrinsic pontine glioma, dysembryoplastic neuroepithelial tumour, ependymal tumour, fibrillary astrocytoma, giant-cell glioblastoma, glioblastoma multiforme, gliomatosis cerebri, gliosarcoma, hemangiopericytoma, medulloblastoma, medulloepithelioma, meningeal carcinomatosis, neuroblastoma, neurocytoma, oligoastrocytoma, oligodendroglioma, optic nerve sheath meningioma, paediatric ependymoma, pilocytic astrocytoma, pinealoblastoma, pineocytoma, pleomorphic anaplastic neuroblastoma, pleomorphic xanthoastrocytoma, primary central nervous system lymphoma, sphenoid wing meningioma, subependymal giant cell astrocytoma, subependymoma, and trilateral retinoblastoma.

8. The method according to claim 6 , wherein the brain cancer is selected from anaplastic astrocytoma, astrocytoma, central neurocytoma, choroid plexus carcinoma, choroid plexus papilloma, choroid plexus tumour, diffuse intrinsic pontine glioma, dysembryoplastic neuroepithelial tumour, ependymal tumour, fibrillary astrocytoma, giant-cell glioblastoma, glioblastoma multiforme, gliomatosis cerebri, gliosarcoma, hemangiopericytoma, medulloblastoma, medulloepithelioma, meningeal carcinomatosis, neuroblastoma, neurocytoma, oligoastrocytoma, oligodendroglioma, optic nerve sheath meningioma, paediatric ependymoma, pilocytic astrocytoma, pinealoblastoma, pineocytoma, pleomorphic anaplastic neuroblastoma, pleomorphic xanthoastrocytoma, primary central nervous system lymphoma, sphenoid wing meningioma, subependymal giant cell astrocytoma, subependymoma, and trilateral retinoblastoma.

9. A method of preventing recurrence of a solid tumor in a subject, comprising administering to the subject an effective amount of a compound according to claim 1 .

10. A method of preventing recurrence of a solid tumor in a subject, comprising administering to the subject a pharmaceutical composition according to claim 2 .

11. The method according to claim 9 , wherein the solid tumor is a brain cancer.

12. The method according to claim 10 , wherein the solid tumor is a brain cancer.

13. The method according to claim 11 , wherein the brain cancer is selected from anaplastic astrocytoma, astrocytoma, central neurocytoma, choroid plexus carcinoma, choroid plexus papilloma, choroid plexus tumour, diffuse intrinsic pontine glioma, dysembryoplastic neuroepithelial tumour, ependymal tumour, fibrillary astrocytoma, giant-cell glioblastoma, glioblastoma multiforme, gliomatosis cerebri, gliosarcoma, hemangiopericytoma, medulloblastoma, medulloepithelioma, meningeal carcinomatosis, neuroblastoma, neurocytoma, oligoastrocytoma, oligodendroglioma, optic nerve sheath meningioma, paediatric ependymoma, pilocytic astrocytoma, pinealoblastoma, pineocytoma, pleomorphic anaplastic neuroblastoma, pleomorphic xanthoastrocytoma, primary central nervous system lymphoma, sphenoid wing meningioma, subependymal giant cell astrocytoma, subependymoma and trilateral retinoblastoma.

14. The method according to claim 12 , wherein the brain cancer is selected from anaplastic astrocytoma, astrocytoma, central neurocytoma, choroid plexus carcinoma, choroid plexus papilloma, choroid plexus tumour, diffuse intrinsic pontine glioma, dysembryoplastic neuroepithelial tumour, ependymal tumour, fibrillary astrocytoma, giant-cell glioblastoma, glioblastoma multiforme, gliomatosis cerebri, gliosarcoma, hemangiopericytoma, medulloblastoma, medulloepithelioma, meningeal carcinomatosis, neuroblastoma, neurocytoma, oligoastrocytoma, oligodendroglioma, optic nerve sheath meningioma, paediatric ependymoma, pilocytic astrocytoma, pinealoblastoma, pineocytoma, pleomorphic anaplastic neuroblastoma, pleomorphic xanthoastrocytoma, primary central nervous system lymphoma, sphenoid wing meningioma, subependymal giant cell astrocytoma, subependymoma and trilateral retinoblastoma.

Assignees

• Univ Sydney

Inventors

• Munoz Lenka
• Gurgis Fadi Maged Shokry
• Akerfeldt Mia
• Kassiou Michael

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C07C237/20

  the carbon skeleton containing six-membered aromatic rings · CPC title

• C07C233/11

  with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings · CPC title

• C07C233/29

  having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings · CPC title

• C07D213/56

  Amides · CPC title